NIRSEVIMAB-ALIP for Respiratory syncytial virus immunisation: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 170 adverse event reports in the FDA FAERS database where NIRSEVIMAB-ALIP was used for Respiratory syncytial virus immunisation.
Most Reported Side Effects for NIRSEVIMAB-ALIP
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 173 | 22.1% | 1 | 127 |
| Respiratory syncytial virus bronchiolitis | 135 | 17.2% | 1 | 72 |
| Bronchiolitis | 83 | 10.6% | 0 | 65 |
| Incorrect dose administered | 80 | 10.2% | 0 | 2 |
| Respiratory syncytial virus infection | 76 | 9.7% | 2 | 54 |
| Pyrexia | 54 | 6.9% | 0 | 29 |
| Cough | 45 | 5.8% | 0 | 25 |
| Respiratory syncytial virus test positive | 36 | 4.6% | 1 | 30 |
| Extra dose administered | 30 | 3.8% | 0 | 0 |
| Product storage error | 30 | 3.8% | 0 | 0 |
| Rash | 25 | 3.2% | 0 | 6 |
| Oxygen therapy | 22 | 2.8% | 0 | 22 |
| Product administered to patient of inappropriate age | 20 | 2.6% | 0 | 0 |
| Respiratory distress | 17 | 2.2% | 0 | 14 |
| Urticaria | 17 | 2.2% | 0 | 4 |
Other Indications for NIRSEVIMAB-ALIP
Antiviral prophylaxis (137)
Immunisation (107)
Prophylaxis (26)
Respiratory syncytial virus infection (22)
Product used for unknown indication (16)